

Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



Research Infrastructures and COVID-19 Research

Responses to the questionnaire

EU-OPENSREEN ERIC

EU-OPENSREEN is a research infrastructure of open screening and medicinal chemistry platforms, which enables small molecule studies in Chemical Biology through the joint use of the European Chemical Biology Library (ECBL), which is composed of 100.000 commercial and a growing number of academic compounds.

SERVICE/S IMPLEMENTED

Access to academic high-throughput screening facilities and medicinal chemistry groups to collaboratively develop novel molecular tool compounds. We accept expression of interest to use our library of bioactive compounds (approx. 2500 compounds including 650 approved drugs, covering more than 1.000 biological targets) for COVID-19 research purposes. For more details contact EU-OPENSREEN at covid-19@eu-openscreen.eu

What stage in COVID-19 intervention your RI is addressing?

EU-OPENSREEN partner sites are currently engaged in a range of activities to study the new coronavirus SARS-CoV-2 with focus on drug discovery including screening campaigns of local repurposing libraries. Check the currently ongoing activities of our partner sites at our EU-OPENSREEN webpage under the COVID-19 dedicated section or contact us at covid-19@eu-openscreen.eu.

Instruments/databases involved:

Automated compound management and high throughput screening instrumentation. An open access database for chemical and biological data will be operational by mid 2020.

How is the proposal submitted?

Who evaluates the proposal?


Scientific team at EU-OPENSREEN ERIC

Is the submission continuous, or linked to a deadline?

Continuous

What is the estimated time from the submission to the access / service provision?

N/A



Research Infrastructures and COVID-19 Research



ACCELERATE is funded by the European Union Framework Programme for Research and Innovation Horizon 2020, under grant agreement 731112



CHARACTERISTICS OF THE ACCESS

Restrictions: No but the fee for using compounds is different for scientists from member states

In the case of analytical facilities, modality of access allowed: Remote and on-site access

If on-site access is allowed, is mobility support available?	NO
Is the access free for non-proprietary research?	NO
Is commercial access available at reduced prices?	NO
Are there limitations regarding the type of samples?	NO
Are there special requirements for shipment of the samples?	NO
Are there specific requirements regarding the preparation or handling of the samples?	NO

Additional comments related to the questions above:

ACCESSIBILITY OF THE PUBLICATION AND DATA

Is there any requirement to publish in open access journals?	NO
Is the data generated associated to metadata and is it publicly available?	YES
If yes, what is the embargo period?	Up to 3 years
Where is the data or metadata published? (e.g. in the institution's catalogue, in other open data repositories, etc).	In an open access database
Do you have further comments about data or metadata?	